MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma
PDF | HTML | How to cite
Metrics: PDF 1513 views | HTML 1853 views | ?
Zhi-Qiang Ning1,*, Hai-lin Lu1,*, Chao Chen1,*, Lin Wang2,*, Wei Cai1, Yan Li1, Ting-hua Cao1, Jing Zhu1, Yong-Qian Shu3,4, Hua Shen3,4
1Department of Oncology, The First People's Hospital of Wujiang District, Suzhou, 215200, China
2Institute of Medcine, University of Zhengzhou, Henan Province, 450000, China
3Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China
4Collaborative Innovation Center for Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
*These authors contributed equally to this work
Hua Shen, email: [email protected]
Yong-Qian Shu, email: [email protected]
Keywords: miRNA-30e, chemosensitivity, gefitinib, HOXA1, lung cancer
Received: May 28, 2016 Accepted: December 06, 2016 Published: December 15, 2016
MicroRNAs (miRNAs) play critical roles in variousbiological processes,including malignancy. Here, we demonstrated that miR-30e levels were markedly reduced in human lung carcinoma specimens in comparisonwith adjacent normal tissues.In addition, miR-30eamounts were starkly lower in the resistant PC9/gefitinib (PC9G) cancer cells compared with PC9 cells. Meanwhile, miR-30eoverexpression inPC9G cells resulted in reduced cell proliferation and migration,reversing drug resistance to gefitinib.Conversely,miR-30e silencing in PC9 cells increased proliferation as well as migration, and conferred resistance to gefitinib.Moreover, HOXA1, which was identified asa new miR-30etarget, plays important roles in regulating cell fate, early developmental patterns and organogenesis.Importantly, miR-30ealso inhibited PC9G growth in vivo. Taken together, these findings demonstrated that miR-30eshould be considered a tumor suppressor miRNA, which could be used in treatinghuman lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.